A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC)

被引:0
作者
E Senkus-Konefka
R Dziadziuszko
E Bednaruk-Młyński
A Pliszka
J Kubrak
A Lewandowska
K Małachowski
M Wierzchowski
M Matecka-Nowak
J Jassem
机构
[1] Medical University of Gdańsk,Department of Oncology and Radiotherapy
[2] Pomeranian Medical Academy,undefined
[3] Strzałowska 22,undefined
[4] Oncology Center,undefined
[5] Dr Izabeli Romanowskiej 2,undefined
[6] Lower Silesian Oncology Center,undefined
[7] Hirszfelda 2,undefined
[8] The Maria Skłodowska-Curie Memorial Cancer Center & Institute of Oncology,undefined
[9] WK Roentgena 5,undefined
[10] Greatpoland Cancer Centre,undefined
来源
British Journal of Cancer | 2005年 / 92卷
关键词
non-small-cell lung cancer; radiotherapy; palliative treatment;
D O I
暂无
中图分类号
学科分类号
摘要
A prospective randomised study compared two palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer (NSCLC). After stratification, 100 patients were randomly assigned to 20 Gy/5 fractions (fr)/5 days (arm A) or 16 Gy/2 fr/day 1 and 8 (arm B). There were 90 men and 10 women aged 47–81 years (mean 66), performance status 1–4 (median 2). The major clinical characteristics and incidence and degree of initial disease-related symptoms were similar in both groups. Treatment effects were assessed using patient's chart, doctor's scoring of symptomatic change and chest X-ray. Study end points included degree and duration of symptomatic relief, treatment side effects, objective response rates and overall survival. A total of 55 patients were assigned to arm A and 45 to arm B. In all, 98 patients received assigned treatment, whereas two patients died before its termination. Treatment tolerance was good and did not differ between study arms. No significant differences between study arms were observed in the degree of relief of all analysed symptoms. Overall survival time differed significantly in favour of arm B (median 8.0 vs 5.3 months; P=0.016). Both irradiation schedules provided comparable, effective palliation of tumour-related symptoms. The improved overall survival and treatment convenience of 2-fraction schedule suggest its usefulness in the routine management of symptomatic inoperable NSCLC.
引用
收藏
页码:1038 / 1045
页数:7
相关论文
共 50 条
  • [11] Response of global quality of life to high-dose palliative radiotherapy for non-small-cell lung cancer
    Schaafsma, J
    Coy, P
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (03): : 691 - 701
  • [12] Clinical evaluation of proton radiotherapy for non-small-cell lung cancer
    Shioyama, Y
    Tokuuye, K
    Okumura, T
    Kagei, K
    Sugahara, S
    Ohara, K
    Akine, Y
    Ishikawa, S
    Satoh, H
    Sekizawa, K
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (01): : 7 - 13
  • [13] Use of palliative radiotherapy among patients with metastatic non-small-cell lung cancer in Puerto Rico
    Quinones-Avila, Valerie
    Ortiz-Ortiz, Karen J.
    Rios-Motta, Ruth
    Marin-Centeno, Heriberto
    Tortolero-Luna, Guillermo
    BMC PALLIATIVE CARE, 2021, 20 (01)
  • [14] Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC)
    Enric Carcereny Costa
    Núria Viñolas Segarra
    Pere Gascón Vilaplana
    Clinical and Translational Oncology, 2008, 10
  • [15] Paclitaxel cisplatin in advanced non-small-cell lung cancer (NSCLC)
    Pirker, R
    Krajnik, G
    Zochbauer, S
    Malayeri, R
    Kneussl, M
    Huber, H
    ANNALS OF ONCOLOGY, 1995, 6 (08) : 833 - 835
  • [16] Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC)
    Carcereny Costa, Enric
    Vinolas Segarra, Nuria
    Gascon Vilaplana, Pere
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2008, 10 (04) : 198 - 203
  • [17] Use of palliative radiotherapy among patients with metastatic non-small-cell lung cancer in Puerto Rico
    Valerie Quiñones-Avila
    Karen J. Ortiz-Ortiz
    Ruth Ríos-Motta
    Heriberto Marín-Centeno
    Guillermo Tortolero-Luna
    BMC Palliative Care, 20
  • [18] The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC)
    Ardizzoni, A
    Antonelli, G
    Grossi, F
    Tixi, L
    Cafferata, M
    Rosso, R
    ANNALS OF ONCOLOGY, 1999, 10 : 13 - 17
  • [19] Palliative Radiotherapy for Non-metastatic Non-small-cell Lung Cancer: Impact of Blood Test Results on Survival
    Nieder, Carsten
    Imingen, Kristian S.
    IN VIVO, 2023, 37 (02): : 771 - 776
  • [20] A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer
    Francesco Grossi
    Filippo de Marinis
    Vittorio Gebbia
    Ferdinando Riccardi
    Orazio Caffo
    Teresa Gamucci
    Francesco Ferraù
    Mario Nardi
    Luca Moscetti
    Luca Boni
    Davide Dondi
    Enzo Galligioni
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 369 - 375